C203 - Comprehensive Migraine Update II: Pharmacologic and Non-Pharmacologic Therapies
Event Time: | Wednesday May 8, 2019 3:30 pm to 5:30 pm |
Topic(s): | Headache, Advanced Practice Provider |
Director(s): | Gretchen Tietjen MD |
Description: | This course is designed to provide a comprehensive understanding of current migraine treatment, with an emphasis on management of chronic migraine. It will highlight the latest developments in pharmacotherapies, procedural therapies, and neurostimulation; describe cognitive behavioral therapies for migraine; and provide online resources for patients. At the conclusion of this program, attendees are invited to "continue the conversation" by engaging in small group conversation with the director and faculty. This program complements Comprehensive Migraine Update I: Diagnosis, Pathophysiology, and Comorbidities, but covers independent topics. |
Completion Message: | Participants should be able to describe acute migraine and recognize risk factors for and treatment of medication overuse headache; discuss preventive strategies, including medications (per evidence-based guidelines), neurostimulation, and procedural treatments; and describe cognitive behavioral therapy and locate resources for patients without access to psychologists. |
CME Credits: | 2 |
Core Competencies: | Patient Care, Medical Knowledge, Practice-Based Learning and Improvement |
Start/End Time | Title | Faculty |
---|---|---|
3:30 PM - 3:40 PM | Introduction | Gretchen E. Tietjen MD |
3:40 PM - 4:10 PM | Advances in Acute Migraine Treatment | Gretchen E. Tietjen MD |
4:10 PM - 4:40 PM | Advances in Preventive Strategies | Bert B. Vargas MD, FAAN |
4:40 PM - 5:10 PM | Behavioral Therapies for Migraine | Frank Andrasik , Elizabeth Seng PhD |
5:10 PM - 5:30 PM | Panel Discussion/Questions and Answers | Faculty |
5:30 PM - 6:00 PM | Continuing the Conversation | Faculty |
Speaker | Disclosure |
---|---|
Frank Andrasik | Dr. Andrasik has nothing to disclose. |
Elizabeth Seng, PhD | Dr. Seng has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with GlaxoSmithKlein plc. and Eli Lily. |
Gretchen E. Tietjen, MD | Dr. Tietjen holds stock and/or stock options in Johnson & Johnson, Stryker. |
Bert B. Vargas, MD, FAAN | Dr. Vargas has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with American Headache Society, Headache Cooperative of the Pacific, ATI, Amgen, Novartis, Allergan, Alder, Teva, Lilly, Upsher-Smith, Biohaven, Promius, and Xoc. Neurology Today. |
Ready to register for the 2019 AAN Annual Meeting?
Related Courses
7:00 AM-9:00 AM |
---|
C247 -
What Do I Do Now?: Emergency and Inpatient Management of Migraine and Other Headache Disorders
Stephanie Nahas MD, FAAN |
11:45 AM-12:45 PM |
Friday Grand Finale: Neuroimaging
|
1:00 PM-3:00 PM |
S59 -
Migraine: Impact, Treatment Patterns and Resource Utilization
|